Yazar "Turkel, Y." seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • [ X ]
    Öğe
    Apelin 13: A promising biomarker for multiple sclerosis.
    (Sage Publications Ltd, 2016) Alpua, M.; Turkel, Y.; Dag, E.; Kisa, U.
    …
  • [ X ]
    Öğe
    The Autonomic Dysfunction And The Quality Of Life In Patients With Erectile Dysfunction: Preliminary Report
    (Wiley-Blackwell, 2014) Daggulli, M.; Tuglu, D.; Turkel, Y.; Sipal, T.; Yuvanc, E.
    …
  • Küçük Resim
    Öğe
    Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study
    (Wiley, 2015) Inan, L. E.; Inan, N.; Karadas, O.; Gul, H. L.; Erdemoglu, A. K.; Turkel, Y.; Akyol, A.
    ObjectivesWe aimed to assess the efficacy of greater occipital nerve (GON) blockade at chronic migraine (CM) treatment. Materials and methodsPatients with CM were randomly divided into two groups of 42. GON blockade was administered four times (once per week) with saline in group A or bupivacaine in group B. After 4weeks of treatment, blinding was removed; in group A, GON blockade was achieved using bupivacaine, while group B continued to receive bupivacaine, and blockade was administered once per month, then followed for 2months. Primary endpoint was the difference in number of headache days, duration of headache, and pain scores. ResultsSeventy-two of 84 patients completed the study. After 1month of treatment, number of headache days had decreased from 16.95.7 to 13.2 +/- 6.7 in group A (P=0.035) and from 18.1 +/- 5.3 to 8.8 +/- 4.8 in group B (P<0.001), (P=0.004, between groups); duration of headache (hour) had decreased from 24.2 +/- 13.7 to 21.2 +/- 13.4 in group A (P=0.223) and from 25.9 +/- 16.3 to 19.3 +/- 11.5 in group B (P<0.001), (P=0.767, between groups). VAS score decreased from 8.1 +/- 0.9 to 6.7 +/- 1.6 in group A (P=0.002) and from 8.4 +/- 1.5 to 5.3 +/- 2.1 in group B (P<0.001), (P=0.004, between groups). After blinding was removed (in 2nd and 3rd month), group A exhibited similar results like group B in 3rd month. ConclusionsOur results suggest that GON blockade with bupivacaine was superior to placebo and was found to be effective, safe, and cost-effective for the treatment of CM. According to our knowledge, this is the first randomized, multicentre, double-blind, and placebo-controlled study in the literature in this field of work.
  • [ X ]
    Öğe
    Greater occipital nerve blocks with bupivacaine in the treatment of chronic migraine. Randomized, multicenter, double-blind, parallel, placebo-controlled study
    (Wiley-Blackwell, 2014) Inan, L.; Inan, N.; Karadas, O.; Gul, H. L.; Erdemoglu, A. K.; Turkel, Y.; Akyol, A.
    [Abstract No tAvailable]
  • [ X ]
    Öğe
    Greater occipital nerve blocks with bupivacaine in the treatment of chronic migraine: randomized, multicenter, double-blind, parallel, placebo-controlled study
    (Springer Heidelberg, 2014) Inan, L.; Inan, N.; Karadas, O.; Gul, H. L.; Erdemoglu, A. K.; Turkel, Y.; Akyol, A.
    …
  • Küçük Resim
    Öğe
    Is there a relationship between Parkinsons disease and Chlamydia pneumoniae
    (Medknow Publications & Media Pvt Ltd, 2015) Turkel, Y.; Dag, E.; Gunes, H. N.; Apan, T.; Yoldas, T. K.
    Objectives: The aim was to investigate a possible relationship between Chlamydia pneumoniae and Parkinsons disease (PD). Study Design: Serum samples obtained from a cohort of 51 patients with PD and from 37 age- and sex-matched controls were assessed for the presence of antibodies. The control group was selected from healthy people. In both groups, 5 mL of blood was taken and after centrifugation frozen at -80 degrees C. Presence and concentration for C. pneumoniae IgM and IgG were determined by the enzyme linked immunosorbent assay (ELISA) and immunofluorescence (IFA), using C. pneumoniae IgG and IgM kit (Euroimmun, Germany). Results: Chlamydia pneumoniae IgG was positive in 50 (98%) patients in ELISA study. C. pneumoniae IgG was positive in 34 (92%) control subjects in ELISA study. C. pneumoniae IgG positivity in patients was slightly higher, but the difference did not reach statistical significance (P = 0.17). No statistically significant difference was found between the patient and the control groups in IFA study (P >= 0.5). C. pneumoniae IgM results (both ELISA and IFA study) was negative in the both PD group and control group.
  • Küçük Resim
    Öğe
    Mini mental state exam versus Montreal cognitive assessment in patients with age-related macular degeneration
    (Verduci Publisher, 2014) Dag, E.; Otrnek, N.; Ornek, K.; Gunay, F.; Turkel, Y.
    OBJECTIVE: To compare the ability of the MMSE and MoCA to identify cognitive dysfunction in patients with age-related macular degeneration (AMD). PATIENTS AND METHODS: The study included 81 (29 female, 52 male) AMD patients who were recruited from the Ophthalmology Department of Kirikkale University during 2012. Participants were screened for cognitive impairment using the MMSE and MoCA. The scores were recorded for all participants. The primary outcome measure was the proportion of patients with a score less than 21 on either test. RESULTS: The percentage of subjects who scored below a cut off of 21/30 was higher on the MoCA (48.1%) than on the MMSE (18.5%) (p = 0.05). The range and standard deviation of scores was larger with the MoCA (7-30, 5.34) than with the MMSE (19-30, 3.26). There was a more pronounced ceiling effect of the MMSE than of the MoCA. The mean MMSE scores of dry-and wet-type AMD patients was significantly higher than the MoCA scores of the same patients (p = 0.000 and p = 0.000). CONCLUSIONS: The MoCA seems to be more sensitive than the MMSE to early cognitive impairment in AMD patients.